卡维地洛对高血压患者的疗效及对其糖脂代谢的影响  

Therapeutic effect of carvedilol on hypertensive patients and its influence on glucose and lipid metabolism

作　　者：何军[1] HE Jun(Department of Cardiology, Affiliated 157th Hospital of Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, 510510, China)

机构地区：[1]广州军区广州总医院附属157医院心内科,广东广州510510

出　　处：《心血管康复医学杂志》2016年第5期520-523,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：广州市科技局计划项目(2015132)~~

摘　　要：目的：观察卡维地洛对高血压的疗效及对其糖脂代谢的影响。方法：选择我院2013年2月~2015年3月期间所收治的116例高血压患者作为研究对象。按照随机数字表法,患者被随机均分为阿替洛尔组（58例,接受阿替洛尔治疗）和卡维地洛组（58例,接受卡维地洛治疗）。观察比较两组患者治疗前、后收缩压（SBP）、舒张压（DBP）、心率（HR）、空腹血糖（FBG）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白-胆固醇（LDL-C）和血肌酐（SCr）水平,临床疗效以及不良反应。结果：与阿替洛尔组比较,卡维地洛组治疗总有效率（87.93%比98.28%）显著升高,P〈0.01。与治疗前比较,两组治疗后上述指标均显著降低（P均〈0.01）;与阿替洛尔组比较,卡维地洛组治疗后SBP[（131.20±11.02）mmHg比（115.62±10.27）mmHg]、DBP[（82.01±6.75）mmHg比（75.68±5.21）mmHg]、HR[（65.14±6.32）次/min比（57.21±4.02）次/min]、FBG[（4.75±1.36）mmol/L比（3.65±1.24）mmol/L]、TC[（2.69±0.58）mmol/L比（2.10±0.41）mmol/L]、TG[（0.96±0.41）mmol/L比（0.72±0.35）mmol/L]、LDL-C[（1.95±0.57）mmol/L比（1.71±0.40）mmol/L]和SCr[（110.23±86.52）μmol/L比（99.97±61.02）μmol/L]水平降低更显著,P均〈0.01。两组均未发生明显不良反应,不良反应发生率（例次,8.62%比3.45%）无显著差异,P〉0.05。结论：与阿替洛尔比较,卡维地洛治疗高血压的临床疗效更佳,值得推广应用。Objective：To observe therapeutic effect of carvedilol on hypertension and its influence on glucose and lipid metabolism.Methods：A total of 116 hypertensive patients treated in our hospital from Feb 2013 to Mar 2015 were selected.According to random number table,patients were randomly and equally divided into atenolol group（n=58,received atenolol therapy）and carvedilol group（n=58,received carvedilol therapy）.Levels of systolic blood pressure（SBP）,diastolic blood pressure（DBP）,heart rate（HR）,fasting blood glucose（FBG）,total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C）and serum creatinine（SCr）before and after treatment,therapeutic effect and incidence of adverse reactions were observed and compared between two groups.Results：Compared with atenolol group,there was significant rise in total effective rate（87.93% vs.98.28%）in carvedilol group,P〈0.01.Compared with before treatment,there were significant reductions in all above indexes in two groups after treatment,P〈0.01all;compared with atenolol group after treatment,there were significant reductions in levels of SBP [（131.20±11.02）mmHg vs.（115.62±10.27）mmHg],DBP[（82.01±6.75）mmHg vs.（75.68±5.21）mmHg],HR [（65.14±6.32）beats/min vs.（57.21±4.02）beats/min],FBG [（4.75±1.36）mmol/L vs.（3.65±1.24）mmol/L],TC [（2.69±0.58）mmol/L vs.（2.10±0.41）mmol/L],TG [（0.96±0.41）mmol/L vs.（0.72±0.35）mmol/L],LDL-C [（1.95±0.57）mmol/L vs.（1.71±0.40）mmol/L]and SCr[（110.23±86.52）μmol/L vs.（99.97±61.02）μmol/L]in carvedilol group,P〈0.01 all.No apparent adverse reactions occurred in two groups,there was no significant difference in incidence rate of adverse reactions（cases,8.62% vs.3.45%）between two groups,P〈0.05.Conclusion：Compared with atenolol,carvedilol possesses better therapeutic effect in treating hypertension,which is worth extending.

关 键 词：高血压 阿替洛尔 卡维地洛 

分 类 号：R544.1[医药卫生—心血管疾病]